AI Tool Comparison
Comparing as AI Medical Research & Clinical Decision SupportInsilico Medicine vs Nabla
Compare features, pricing, pros & cons, and user ratings to decide which AI tool is best for your needs.
Insilico Medicine
VS
Nabla
Verdict by Category
AI content generation failed. Refresh the page to try again.
Detailed Comparison
Feature
Insilico Medicine
Nabla
Pricing
CustomInsilico Medicine operates through two revenue streams: platform licensing and internal drug pipeline development.
Platform access: Pharmaceutical and biotech companies license the Pharma.AI platform (PandaOmics, Chemistry42, InClinico) through enterprise agreements for target identification, molecule design, and clinical prediction. Revenue is structured as upfront platform fees, milestone payments tied to drug program progress, and royalties on commercialized drugs.
Pipeline partnerships: Insilico licenses its AI-discovered drug candidates to pharma companies (e.g., Sanofi, Exelixis) for multi-million/billion dollar deals with upfront + milestone structures. Total revenue grew from $4.5M (2021) to $85M (2024). Contact Insilico through insilico.com for licensing and partnership inquiries.
FreemiumNabla does not publish exact pricing on its official website; the primary calls-to-action are a free trial (via app.nabla.com) and "Talk to our team" for enterprise sales. Third-party sources consistently report a free tier with usage limits, with paid individual/clinician plans starting around $119/month per provider and higher tiers reported near $239/month per provider. Larger health-system deployments — Nabla's core market, spanning 130+ organizations — are sold via custom enterprise contracts with volume-based pricing, with independent estimates placing typical enterprise rates in the $150-$400/month per provider range depending on scale, EHR integration depth, and features. Exact costs require a sales conversation with Nabla.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Productivity ToolsAI Developer APIs & Platforms
Summary
Generative AI drug discovery platform — from target identification to Phase 3 clinical trials with Pharma.AI
Ambient AI that turns patient visits into clinical notes, dictation, and coding — right inside the EHR
Insilico Medicine Pros & Cons
Pros
- World's most advanced fully AI-designed drug — rentosertib in Phase 3 for IPF (2026)
- End-to-end Pharma.AI platform covers target ID through clinical prediction in one system
- 300+ patents and 200+ peer-reviewed papers — strongest scientific publication record in AI drug discovery
- Revenue grew from $4.5M to $85M in 3 years — commercially proven licensing model
- Automated robotic lab in Suzhou closing the loop between AI design and physical testing
- Global presence: US, China, Canada, Middle East — with partnerships across big pharma
- Listed on Hong Kong Stock Exchange (HKEX: 3696) — public company with institutional backing
Cons
- Pipeline still in early-to-mid clinical stages — commercial drugs not yet approved
- Business model complexity — revenue from licensing deals is lumpy and milestone-dependent
- Dual-track model (platform + internal pipeline) adds operational complexity
- Regulatory timelines in pharma are long — AI acceleration doesn't remove all delays
- Listed on HKEX (Hong Kong) — less accessible to US institutional investors
Nabla Pros & Cons
Pros
- Fast note generation, roughly five seconds, that closely mirrors real clinical documentation in independent tests
- Deep native integration with Epic and other major EHRs rather than copy-paste workflows
- Broad specialty and language coverage suited to large, diverse health systems
- Strong compliance posture (HIPAA, SOC 2 Type 2, ISO 27001, GDPR) with configurable data retention
- Backed by peer-reviewed evidence, including a NEJM AI randomized trial showing documentation-time reductions
- Combines documentation, dictation, and coding in one platform instead of separate point tools
Cons
- Pricing isn't published; individuals and smaller practices must go through a sales conversation or rely on third-party estimates to budget
- Primarily built for hospitals and health systems, so solo clinicians and small practices may find it less tailored than SMB-focused scribes
- Relies on ambient recording, so encounters where a patient or clinician can't or won't be recorded aren't well supported
- Some independent reviews note limited customization and quality drop-off on complex, multi-problem visits
- Mobile app store ratings are mixed and based on a relatively small number of reviews compared to the platform's overall clinician base